| Date | Title | Description |
| 08.07.2025 | Narcolepsy Network Announces its 38th Annual Conference | A Weekend of Learning, Community and Hope
CAMAS, Wash., July 8, 2025 /PRNewswire-PRWeb/ -- Narcolepsy Network is delighted to announce its 38th Annual Conference, taking place Friday, October 24 through Sunday, October 26, 2025, at the Roya... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 25.06.2024 | HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) | FDA confirms the favorable benefit-risk profile of WAKIX
Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product or indication launch annually over the ... |
| 30.04.2024 | Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Seco... |
| 11.04.2024 | HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST | PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and ... |
| 07.02.2023 | HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023 | PLYMOUTH MEETING, Pa., Feb. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for pati... |
| 03.01.2023 | This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year | Jeff Aronin, CEO of Paragon Biosciences and founder of Emalex Biosciences. Paragon Biosciences
Emalex Bioscience is developing a new treatment for Tourette Syndrome. The disease affects around 1 in 160 children and has no cure. Emalex found... |
| 21.07.2022 | Many Productive Developments for Jeff Aronin’s Paragon Biosciences’ Portfolio Companies in the First Half of 2022 | David Thompson, Tech Times 21 July 2022, 11:07 am
(Photo : Paragon Biosciences)
Jeff Aronin's Paragon Biosciences and its portfolio companies have seen great growth in the first two quarters of 2022 on its mission to find innovative treatme... |
| 14.02.2022 | Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results | PLYMOUTH MEETING, Pa., Feb. 14, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare n... |
| 01.12.2021 | Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia | PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare ne... |
| 09.11.2021 | Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates | WAKIX® (pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020
Average Number of Patients on WAKIX Increased to ~3,500
Announced Inclusion of WAKIX in American Academy of Sleep Medicine's... |
| 09.11.2021 | HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND BUSINESS UPDATES - Form 8-K | HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND BUSINESS UPDATES
WAKIX®(pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020
Average Number of Patients on WAKIX Inc... |
| 26.10.2021 | Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results | PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi... |
| 21.10.2021 | Harmony Biosciences : to be Added to the S&P SmallCap 600® Index | PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi... |
| 22.09.2021 | HARMONY BIOSCIENCES : ANNOUNCES WINNERS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART ON THIRD ANNUAL WORLD NARCOLEPSY DAY | Print HARMONY BIOSCIENCES ANNOUNCES WINNERS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART ON THIRD ANNUAL WORLD NARCOLEPSY DAY
Eight organizations awarded with more than $180,000 in patient-centric funding for the narcolepsy and rare d... |
| 02.09.2021 | Harmony Biosciences Announces Inclusion Of WAKIX® (pitolisant) In American Academy Of Sleep Medicine's Updated Clinical Practice Guideline | |
| 02.09.2021 | HARMONY BIOSCIENCES : ANNOUNCES INCLUSION OF WAKIX® (PITOLISANT) IN AMERICAN ACADEMY OF SLEEP MEDICINE'S UPDATED CLINICAL PRACTICE GUIDELINE | Print HARMONY BIOSCIENCES ANNOUNCES INCLUSION OF WAKIX® (PITOLISANT) IN AMERICAN ACADEMY OF SLEEP MEDICINE'S UPDATED CLINICAL PRACTICE GUIDELINE
Updated guideline recommends use of WAKIX to treat excessive daytime sleepiness and cataplexy i... |
| 10.08.2021 | Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration | |
| 10.08.2021 | Harmony Biosciences : And Blackstone Enter Into Strategic Financing Collaboration | PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patient... |
| 10.08.2021 | Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration | PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patient... |
| 29.07.2021 | Harmony Biosciences : John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 Greater Philadelphia Award Winner | PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living wit... |
| 27.07.2021 | Harmony Biosciences : Announces Date Of Second Quarter 2021 Financial Results | PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi... |
| 10.06.2021 | HARMONY BIOSCIENCES : PRESENTS NEW ANALYSIS DEMONSTRATING THE CLINICAL IMPACT OF WAKIX® (PITOLISANT) AT THE SLEEP 2021 ANNUAL MEETING | Print HARMONY BIOSCIENCES PRESENTS NEW ANALYSIS DEMONSTRATING THE CLINICAL IMPACT OF WAKIX® (PITOLISANT) AT THE SLEEP 2021 ANNUAL MEETING
Data highlight the clinical effectiveness of WAKIX for excessive daytime sleepiness and cataplexy in a... |
| 10.06.2021 | Harmony Biosciences : C O R R E C T I O N -- Harmony Biosciences/ | In the news release, Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting, issued June 10, 2021 by Harmony Biosciences over PR Newswire, we are advised by the company that the... |
| 09.06.2021 | Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9 | |
| 09.06.2021 | HARMONY BIOSCIENCES HOLDINGS, INC.
Harmony Biosciences : Announces Applications for 2021 Patients At The Heart Grant Program Open June 9 | PLYMOUTH MEETING, Pa., June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with ... |
| 18.05.2021 | HARMONY BIOSCIENCES HOLDINGS, INC.
Harmony Biosciences : John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors | PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with ... |
| 27.04.2021 | Harmony Biosciences : Announces Date of First Quarter 2021 Financial Results | PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap... |
| 07.04.2021 | HARMONY BIOSCIENCES HOLDINGS, INC.
Harmony Biosciences : Launches Grant Program To Address Inequities In The Delivery Of Healthcare In Patients With Sleep Disorders | PLYMOUTH MEETING, Pa., April 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with... |
| 07.04.2021 | Harmony Biosciences Launches Grant Program To Address Inequities In The Delivery Of Healthcare In Patients With Sleep Disorders | |
| 15.03.2021 | Harmony Biosciences : Appoints Sandip Kapadia as Chief Financial Officer | PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living wit... |
| 15.03.2021 | HARMONY BIOSCIENCES HOLDINGS, INC.
Harmony Biosciences : Appoints Sandip Kapadia as Chief Financial Officer | PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living wit... |
| 04.03.2021 | Harmony Biosciences Announces Date Of Fourth Quarter And Full Year 2020 Financial Results | |
| 17.12.2020 | Harmony Biosciences To Be Added To Russell 2000® And Russell 3000® Indexes | |
| 14.10.2020 | Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy | |
| 28.08.2020 | Harmony Biosciences Presents Efficacy And Safety Analyses For WAKIX® (pitolisant) At Virtual SLEEP 2020 | |
| 20.08.2020 | Money Moves: 3 life science and health IT companies raise funds — and one goes public | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly.
Harmony Biosciences, a Plymouth Meeting-based pharmaceutical company that develops and commercialize... |
| 27.01.2020 | Harmony Biosciences Secures $200 Million Debt Facility | - |
| 13.03.2019 | CRG to Provide $200M Debt Facility to Harmony | Harmony Biosciences, LLC (Harmony) a private biopharmaceutical company dedicated to developing and commercializing novel treatment options for people living with rare diseases, announced today that it has entered into a $200 million debt fa... |
| 10.10.2017 | Term Sheet — Tuesday, October 10 | BIG MONEY, FEW DEALS
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
But here’s the twist. Investors are pumping larger amounts of capital into fewer companies. In other words, a small pe... |
| 09.10.2017 | Harmony Biosciences Raises $270M | Biopharmaceutical company Harmony Biosciences, LLC, a member of the Paragon Biosciences (Paragon) corporate family, today announced it has acquired the exclusive US right to develop, register and market the drug pitolisant from French compa... |
| 06.10.2017 | Harmony Biosciences Raises $270M in Equity Financing | Harmony Biosciences, a Plymouth Meeting, PA-based biopharmaceutical company and a member of the Paragon Biosciences corporate family, raised $270M in equity financing.
Backers included Valor Equity Partners, Fidelity Management & Resear... |
| - | HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1 | PLYMOUTH MEETING, Pa., June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myot... |